Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
Peng X, Long X, Liu L, Zeng L, Yang H, Jiang W, Liao D, Li K, Wang J, Lizaso A, Mao X, Xu Q, Mansfield AS, Yang N, Zhang Y. Peng X, et al. Among authors: liao d. Eur J Cancer. 2020 Dec;141:199-208. doi: 10.1016/j.ejca.2020.10.005. Epub 2020 Nov 7. Eur J Cancer. 2020. PMID: 33171317
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
Zeng L, Xiao L, Jiang W, Yang H, Hu D, Xia C, Li Y, Zhou C, Xiong Y, Liu L, Liao D, Guan R, Li K, Wang J, Zhang Y, Yang N, Mansfield AS. Zeng L, et al. Among authors: liao d. Lung Cancer. 2020 Mar;141:82-88. doi: 10.1016/j.lungcan.2020.01.009. Epub 2020 Jan 13. Lung Cancer. 2020. PMID: 31982639
Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study.
Wei W, Zhou J, Zhang Q, Liao DH, Liu QD, Zhong BL, Liang ZB, Zhang YC, Jiang R, Liu GY, Xu CY, Li Zhou H, Zhu SY, Yang N, Jiang W, Liu ZG. Wei W, et al. Cancer Med. 2020 Apr;9(8):2820-2832. doi: 10.1002/cam4.2937. Epub 2020 Feb 26. Cancer Med. 2020. PMID: 32100444 Free PMC article. Clinical Trial.
Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC.
Zhang Y, Zeng L, Zhou C, Li Y, Wu L, Xia C, Jiang W, Hu Y, Liao D, Xiao L, Liu L, Yang H, Xiong Y, Guan R, Lizaso A, Mansfield AS, Yang N. Zhang Y, et al. Among authors: liao d. J Thorac Oncol. 2020 Jun;15(6):1027-1036. doi: 10.1016/j.jtho.2020.02.007. Epub 2020 Feb 27. J Thorac Oncol. 2020. PMID: 32112982 Free article.
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
Zhang X, Xiong Y, Xia Q, Wu F, Liu L, Zhou Y, Zeng L, Zhou C, Xia C, Jiang W, Liao D, Xiao L, Liu L, Yang H, Guan R, Li K, Wang J, Lei G, Zhang Y, Yang N. Zhang X, et al. Among authors: liao d. JAMA Netw Open. 2020 Mar 2;3(3):e201226. doi: 10.1001/jamanetworkopen.2020.1226. JAMA Netw Open. 2020. PMID: 32191330 Free PMC article. Clinical Trial.
Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients.
Liao D, Liu Z, Zhang Y, Liu N, Yao D, Cao L, Chen Y, Fu Y, Yang N, Xiang D. Liao D, et al. Front Pharmacol. 2020 May 8;11:664. doi: 10.3389/fphar.2020.00664. eCollection 2020. Front Pharmacol. 2020. PMID: 32457635 Free PMC article.
2,267 results